• Home
  •  / Burzynski Research Institute

Burzynski Research Institute

OverviewSuggest Edit

Burzynski Research Institute (BRI) is a biopharmaceutical company committed to developing, and delivering cancer therapies based on genomic and epigenomic principles. Currently research and development efforts are focused on investigational agents called Antineoplastons (ANPs) and their efficacy and safety in the treatment of advanced cancers, especially malignant brain tumors.

TypePublic
Founded1984
HQHouston, TX, USMap
Websiteburzynskiresearch.com

Locations

Burzynski Research Institute is headquartered in
Houston, United States

Location Map
All Locations (2)

Latest Updates

Revenue (FY, 2020)$0
Share Price (Jan 2021)$0
Cybersecurity ratingAMore

Burzynski Research Institute Office Locations

Burzynski Research Institute has offices in Houston and Stafford
Houston, TX, US (HQ)
9432 Katy Fwy
Stafford, TX, US
12707 Trinity Dr
Show all (2)

Burzynski Research Institute Financials and Metrics

Burzynski Research Institute Revenue

USD

Net income (FY, 2020)

(1.6m)

EBIT (FY, 2020)

(1.6m)

Market capitalization (25-Jan-2021)

3.7m

Closing stock price (25-Jan-2021)

0.0

Cash (29-Feb-2020)

163.0
Burzynski Research Institute's current market capitalization is $3.7 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

231.4k450.7k307.7k182.8k157.1k179.1k332.6k491.8k431.8k

R&D expense

6.9m6.0m4.0m2.7m1.8m1.3m1.3m1.1m1.2m

Operating expense total

7.2m6.5m4.3m2.9m2.0m1.5m1.6m1.6m1.6m
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

General and administrative expense

44.1k75.5k141.5k297.1k99.2k143.8k85.6k45.2k60.4k22.3k53.2k52.1k24.6k27.0k20.3k91.7k35.0k94.7k100.6k57.7k128.8k141.2k117.6k135.6k110.5k132.0k

R&D expense

1.7m1.8m1.5m1.5m1.4m1.2m1.0m937.5k780.3k704.2k654.3k572.2k485.5k433.0k349.5k309.9k348.0k367.5k325.1k343.4k280.7k308.5k322.1k332.7k299.7k339.7k

Operating expense total

1.8m1.8m1.7m1.8m1.5m1.4m1.1m982.7k840.7k726.5k707.5k624.4k510.1k460.0k369.8k401.6k383.0k462.2k425.7k401.1k409.6k449.7k439.6k468.3k410.2k471.7k
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

17.3k1.2k229.02.3k3.3k731.0506.0708.0163.0

Prepaid Expenses

28.4k21.5k19.7k

Current Assets

17.3k1.2k229.02.3k3.3k10.7k28.9k22.2k19.9k

PP&E

3.4k2.7k2.1k1.4k684.022.4k22.4k
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

22.5k16.1k14.9k14.1k2.6k1.3k846.084.01.9k5.8k2.0k480.0502.0590.0859.0424.0882.0382.0504.03.4k206.0409.0486.03.1k1.1k221.0

Prepaid Expenses

32.6k16.7k44.9k33.2k9.7k45.0k32.3k

Current Assets

22.5k16.1k14.9k14.1k2.6k1.3k846.084.01.9k5.8k2.0k480.0502.0590.0859.0424.0882.0382.0504.036.1k16.9k45.3k33.7k12.9k46.1k32.6k

PP&E

3.8k3.6k3.2k3.1k2.9k2.6k2.4k2.2k1.9k1.7k1.5k1.2k1.0k855.0513.0342.0171.0
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(7.2m)(6.5m)(4.3m)(2.9m)(2.0m)(1.5m)(1.6m)(1.6m)(1.6m)

Depreciation and Amortization

701.0683.0684.0684.0684.0684.0

Accounts Payable

(27.0k)35.2k66.8k(14.4k)(35.5k)(44.7k)22.3k59.1k(40.3k)

Cash From Operating Activities

(504.1k)(671.3k)(438.4k)(353.7k)(251.0k)(314.5k)(319.5k)(477.5k)(530.1k)
Quarterly
USDQ2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(3.3m)(5.1m)(1.7m)(3.5m)(5.0m)(1.4m)(2.5m)(3.4m)(840.9k)(1.6m)(2.3m)(624.5k)(1.1m)(1.6m)(370.0k)(771.8k)(1.2m)(461.2k)(887.0k)(1.3m)(409.6k)(859.2k)(1.3m)(468.3k)(878.5k)(1.4m)

Depreciation and Amortization

354.0531.0171.0342.0513.0171.0342.0513.0171.0342.0513.0171.0342.0513.0171.0342.0513.0

Accounts Payable

(36.0k)(35.6k)43.1k(1.7k)40.7k(7.6k)105.5k115.6k(5.9k)(880.0)(23.3k)(18.4k)(7.1k)(12.5k)(18.2k)14.2k(15.5k)40.5k41.1k48.4k23.2k53.7k56.3k(3.9k)(8.1k)(7.0k)

Cash From Operating Activities

(271.9k)(388.5k)(138.9k)(427.9k)(538.3k)(162.6k)(253.2k)(340.2k)(129.0k)(204.5k)(317.3k)(78.6k)(111.5k)(157.4k)(78.0k)(139.2k)(230.8k)(54.6k)(144.0k)(213.5k)(116.3k)(242.6k)(371.6k)(135.8k)(281.9k)(430.0k)
show all
USDQ2, 2012

Financial Leverage

-2.5 x
Show all financial metrics

Burzynski Research Institute Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

Learn more about our premium products
SecurityScorecard logo

Burzynski Research Institute Online and Social Media Presence

Burzynski Research Institute's Trends

Embed Graph

 Burzynski Research Institute Frequently Asked Questions

  • When was Burzynski Research Institute founded?

    Burzynski Research Institute was founded in 1984.

  • Who are Burzynski Research Institute competitors?

    Competitors of Burzynski Research Institute include Alpine Immune Sciences, Loxo Oncology and Rexahn Pharmaceuticals.

  • Where is Burzynski Research Institute headquarters?

    Burzynski Research Institute headquarters is located at 9432 Katy Fwy, Houston.

  • Where are Burzynski Research Institute offices?

    Burzynski Research Institute has offices in Houston and Stafford.

  • How many offices does Burzynski Research Institute have?

    Burzynski Research Institute has 2 offices.